Safety and effectiveness of rivaroxaban thromboprophylaxis in adrenocorticotropic hormone–dependent Cushing syndrome
In our cohort, VTE incidence was 13.8% without prophylaxis and did not occur after the introduction of routine rivaroxaban. Prophylactic oral rivaroxaban in ACTH-dependent CS was safe and effective in preventing new, recurrent, perioperative, and postoperative VTE events, supporting its early initiation at diagnosis and continuation through the peri-and postoperative period.
Authors
- Florian Wernig (ORCID: https://orcid.org/0000-0001-5914-9318)
- Katharine Lazarus (ORCID: https://orcid.org/0000-0003-0758-7839)
- Zin Htut
- Deborah Papadopoulou (ORCID: https://orcid.org/0000-0002-7557-7803)
- Karim Meeran
- niamh Martin
- Aastha Mundhra
Institutions
- Imperial College Healthcare NHS Trust (GB)
- Imperial College London (GB)
Publication Details
- Journal
- The Journal of Clinical Endocrinology & Metabolism
- Published
- 2026-01-14
- DOI
- https://doi.org/10.1210/clinem/dgag014
- Primary Topic
- Pituitary Gland Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00